However, when the potentially compounding biomarkers (Myc+, Bcl-2+, and TP53 mutations, Table 1) were also included in the multivariate analysis, c-Rel+ showed significant prognostic value for poorer overall survival in the whole and ABC-DLBCL cohorts. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.